Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod in steroid-resistant/relapse immune thrombocytopenia
NCT05302024Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iguratimod in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Primary endpoint: Durable response at 6 months. Status: unknown.
02
Drugs
iguratimod
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05302024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302024.